NEW YORK (GenomeWeb News) – Bio-Rad Laboratories and Myriad RBM said after the close of the market on Tuesday they are partnering to develop and distribute immunoassays kits.
Myriad RBM, a subsidiary of Myriad Genetics formed when it acquired Rules-Based Medicine last year, is granting Bio-Rad exclusive distribution rights, for research purposes, to it catalog of quantitative multiplexed immunoassays to run on Bio-Rad's Bio-Plex 200, Bio-Plex 3D, and Bio-Plex MagPix instruments.
Myriad RBM's assay provide for multiplex testing of samples with very low volumes for the studies focused on toxicology, oncology, immunology, and cardiovascular and other diseases.
"This agreement combines Myriad RBM's industry-leading menu of multiplexed immunoassays with Bio-Rad's unrivaled global commercial distribution capabilities," Craig Benson, President of Myriad RBM, said in a statement. "Our partnership with Bio-Rad will help researchers and clinicians on the front lines of medicine to develop biomarker profiles that may predict, detect, or monitor disease progression in an effort to optimize treatment and improve patient care."